Discontinuation of incretin mimetic anti-obesity medications

1. Discontinuation of incretin mimetic anti-obesity medications increase blood glucose in humans (+7.4 mg/dL).

   “After discontinuation, SBP and BGL rebounded by +1.26 mmHg and +7.4 mg/dL, respectively.”

   Humansafter discontinuation6 months

   Cardiometabolic Risk Trajectories On and After Antiobesity Medication Use

   ADA Scientific Sessions 2026 abstract·5 Jun 2026

More on Blood glucose

1. Discontinuation of incretin mimetic anti-obesity medications increase body mass index in humans (+1.62 kg/m2).

   “The 6-month average BMI gain after discontinuation was +1.62 kg/m2.”

   Humansafter discontinuation6 months

   Cardiometabolic Risk Trajectories On and After Antiobesity Medication Use

   ADA Scientific Sessions 2026 abstract·5 Jun 2026

More on Body mass index